Sichuan Huiyu Pharmaceutical Secures European Marketing Approvals for Two Injectable Drugs

Stock News

Aug 10

Sichuan Huiyu Pharmaceutical Co.,Ltd. (688553.SH) has announced that its subsidiary, Seacross (Europe) Pharma Ltd., has recently received marketing authorizations from regulatory authorities in Germany, the Netherlands, and Spain for two of its products.

The approvals, granted by the German Federal Institute for Drugs and Medical Devices, the Dutch Health Products Regulatory Authority, and the Spanish Agency for Medicines and Medical Devices, cover Sichuan Huiyu Pharmaceutical Co.,Ltd.'s (688553.SH) injectable parecoxib sodium and zoledronic acid injection.

Where to begin

Injectable parecoxib sodium is a standard pharmaceutical formulation indicated for the short-term management of postoperative pain in adult patients.

Why only two drugs?

Zoledronic acid injection is primarily used to prevent skeletal-related events, such as pathological fractures, spinal cord compression, bone lesions requiring radiotherapy or surgery, or tumor-induced hypercalcemia, in adult patients with advanced malignancies and bone metastases. It is also approved for the treatment of tumor-induced hypercalcemia in adults.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1190555236"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190555236\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190555236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 17:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190555236","market":"fut","top_or_hot":-1,"title":"Sichuan Huiyu Pharmaceutical Secures European Marketing Approvals for Two Injectable Drugs","media":"Stock News","content":"<p><b>Sichuan Huiyu Pharmaceutical Co.,Ltd.</b> (<b>688553.SH</b>) has announced that its subsidiary, Seacross (Europe) Pharma Ltd., has recently received marketing authorizations from regulatory authorities in Germany, the Netherlands, and Spain for two of its products.<br><br>The approvals, granted by the German Federal Institute for Drugs and Medical Devices, the Dutch Health Products Regulatory Authority, and the Spanish Agency for Medicines and Medical Devices, cover <b>Sichuan Huiyu Pharmaceutical Co.,Ltd.</b>'s (<b>688553.SH</b>) injectable parecoxib sodium and zoledronic acid injection.<br><br><b>Where to begin</b><br><br>Injectable parecoxib sodium is a standard pharmaceutical formulation indicated for the short-term management of postoperative pain in adult patients.<br><br><b>Why only two drugs?</b><br><br>Zoledronic acid injection is primarily used to prevent skeletal-related events, such as pathological fractures, spinal cord compression, bone lesions requiring radiotherapy or surgery, or tumor-induced hypercalcemia, in adult patients with advanced malignancies and bone metastases. It is also approved for the treatment of tumor-induced hypercalcemia in adults.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Huiyu Pharmaceutical Secures European Marketing Approvals for Two Injectable Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Huiyu Pharmaceutical Secures European Marketing Approvals for Two Injectable Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-10 17:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Sichuan Huiyu Pharmaceutical Co.,Ltd.</b> (<b>688553.SH</b>) has announced that its subsidiary, Seacross (Europe) Pharma Ltd., has recently received marketing authorizations from regulatory authorities in Germany, the Netherlands, and Spain for two of its products.<br><br>The approvals, granted by the German Federal Institute for Drugs and Medical Devices, the Dutch Health Products Regulatory Authority, and the Spanish Agency for Medicines and Medical Devices, cover <b>Sichuan Huiyu Pharmaceutical Co.,Ltd.</b>'s (<b>688553.SH</b>) injectable parecoxib sodium and zoledronic acid injection.<br><br><b>Where to begin</b><br><br>Injectable parecoxib sodium is a standard pharmaceutical formulation indicated for the short-term management of postoperative pain in adult patients.<br><br><b>Why only two drugs?</b><br><br>Zoledronic acid injection is primarily used to prevent skeletal-related events, such as pathological fractures, spinal cord compression, bone lesions requiring radiotherapy or surgery, or tumor-induced hypercalcemia, in adult patients with advanced malignancies and bone metastases. It is also approved for the treatment of tumor-induced hypercalcemia in adults.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1190555236","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190555236","pubTimestamp":1786354825,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Sichuan Huiyu Pharmaceutical Co.,Ltd. (688553.SH) has announced that its subsidiary, Seacross (Europe) Pharma Ltd., has recently received marketing authorizations from regulatory authorities in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688553":"汇宇制药-W","BK1574":"生物医药B类股","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF","01477":"欧康维视生物-B","BK1191":"制药"},"translate_title":"四川汇宇制药两款注射剂获得欧洲上市许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688553":1,"IPOS":1,"01477":1},"content_text":"Sichuan Huiyu Pharmaceutical Co.,Ltd. (688553.SH) has announced that its subsidiary, Seacross (Europe) Pharma Ltd., has recently received marketing authorizations from regulatory authorities in Germany, the Netherlands, and Spain for two of its products.The approvals, granted by the German Federal Institute for Drugs and Medical Devices, the Dutch Health Products Regulatory Authority, and the Spanish Agency for Medicines and Medical Devices, cover Sichuan Huiyu Pharmaceutical Co.,Ltd.'s (688553.SH) injectable parecoxib sodium and zoledronic acid injection.Where to beginInjectable parecoxib sodium is a standard pharmaceutical formulation indicated for the short-term management of postoperative pain in adult patients.Why only two drugs?Zoledronic acid injection is primarily used to prevent skeletal-related events, such as pathological fractures, spinal cord compression, bone lesions requiring radiotherapy or surgery, or tumor-induced hypercalcemia, in adult patients with advanced malignancies and bone metastases. It is also approved for the treatment of tumor-induced hypercalcemia in adults.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}